<p>多伦多，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)</strong>（“Profound” 或 “公司”）欣然宣布，已增加其于 2025 年 12 月 19 日之前宣布的私募配售规模（“发行”），以便容纳一位长期现有投资者的参与。</p>
<p>公司现在将在此次发行中筹集最多 645 万美元的毛收益，通过发行最多 921,428 股普通股，价格为每股 7.00 美元。</p>
<p>根据此次发行出售的普通股将受到四个月加一天的持有期限制，从发行的成交日期开始计算。预计此次发行的成交将在 2025 年 12 月 30 日或之前进行。</p>
<p>公司打算将此次发行的净收益用于扩大销售和市场营销、营运资金、研发、战略交易和一般企业用途。</p>
<p>此次发行下不会向美国购买者出售任何证券，本新闻稿不构成在美国或任何在该司法管辖区内此类要约、招揽或销售在未符合或注册该司法管辖区证券法之前的要约。根据此次发行提供的证券尚未，也不会根据美国证券法进行注册，并且在未注册或适用的美国注册要求和适用的美国州证券法的豁免情况下，这些证券不得在美国境内或向美国人士提供或出售。</p>
<p><strong>关于 Profound Medical Corp.</strong></p>
<p>Profound 是一家商业阶段的医疗设备公司，开发和销售基于人工智能的、MRI 引导的、无切口的疾病组织消融疗法。</p>
<p>Profound 正在商业化 TULSA-PRO®，这是一项结合实时 MRI、AI 增强规划、机器人驱动的经尿道超声和闭环温度反馈控制的技术。使用 TULSA-PRO 系统进行的 TULSA 程序™有潜力成为整个前列腺疾病谱的主流治疗方式；涵盖低、中、高风险前列腺癌；同时适用于同时患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；仅患有 BPH 的男性；以及需要针对放射性复发局部前列腺癌进行挽救治疗的患者。TULSA 程序采用实时 MRI 引导，以精确保护患者的尿失禁和性功能，同时通过精确的声波吸收技术将目标前列腺组织加热至 55-57°C。TULSA 是一种无切口和无辐射的 “一次性” 程序，在单次会话中完成，耗时数小时。几乎所有形状和大小的前列腺都可以安全、有效和高效地使用 TULSA 进行治疗。该程序没有出血；不需要住院；大多数 TULSA 患者报告迅速恢复到正常日常生活。TULSA-PRO 已获得 CE 标记、加拿大卫生部批准，并获得美国食品药品监督管理局（“FDA”）的 510(k) 清关。</p>
<p>Profound 还在商业化 Sonalleve®，这是一种创新的治疗平台，已获得 CE 标记，用于治疗子宫肌瘤、腺肌症、骨转移疼痛缓解、纤维瘤和骨样骨瘤。Sonalleve 还获得了中国国家药品监督管理局的批准，用于无创治疗子宫肌瘤，并在美国获得人道设备豁免下的 FDA 批准，用于治疗骨样骨瘤。Profound 正在早期阶段探索 Sonalleve 的其他潜在治疗市场，该技术已显示出临床应用，例如无创消融腹部癌症和癌症治疗的高温疗法。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告包含关于 Profound 及其业务的前瞻性声明，这些声明可能包括但不限于与公司预期的收益使用和发行结束相关的声明。通常，但并非总是，前瞻性声明可以通过使用诸如 “计划”、“预计”、“期望”、“安排”、“打算”、“考虑”、“预期”、“相信”、“提议” 或这些词语和短语的变体（包括否定变体）来识别，或者声明某些行动、事件或结果 “可能”、“可以”、“将”、“可能会” 或 “将会” 被采取、发生或实现。这些声明基于 Profound 管理层当前的预期。本公告中讨论的前瞻性事件和情况，可能不会在某些特定日期之前发生，或者根本不会发生，并且可能因影响公司的已知和未知风险因素和不确定性而有实质性差异。尽管 Profound 已尝试识别可能导致实际行动、事件或结果与前瞻性声明中描述的内容有实质性差异的重要因素，但可能还有其他因素导致行动、事件或结果与预期、估计或打算的内容有所不同。没有任何前瞻性声明可以得到保证。可能导致实际结果与前瞻性声明中所列内容有实质性差异的其他因素和风险已在 Profound 的 10-K 表格年度报告及其他向美国和加拿大证券监管机构提交的文件中进行了描述，这些文件可在 www.sedarplus.ca 和 www.sec.gov 获取。除非适用的证券法要求，否则前瞻性声明仅在作出声明的日期有效，Profound 没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律另有要求的除外。</p>
<p><strong>如需更多信息，请联系：</strong></p>
<p>Stephen Kilmer</p>
<p>投资者关系</p>
<p>skilmer@profoundmedical.com</p>
<p>电话：647.872.4849</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXlOeU0zTXpNMU9UazFJekl3TVRnMU5EYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXlOeU0zTXpNMU9UazFJekl3TVRnMU5EYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjEwNzdjNjItZTFkOC00ZmE4LTlkMGItMjU4YjAxOTcwNzgxLTEwMzAxMTktMjAyNS0xMi0yNC1lbg==/tiny/Profound-Medical-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjEwNzdjNjItZTFkOC00ZmE4LTlkMGItMjU4YjAxOTcwNzgxLTEwMzAxMTktMjAyNS0xMi0yNC1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

PROF

<p>Profound Medical Corp. 已将其私募的规模扩大至最高 645 万美元，计划发行 921,428 股普通股，每股价格为 7.00 美元。募集资金将用于销售和市场扩展、营运资金、研发、战略交易以及一般企业用途。该发行预计将在 2025 年 12 月 30 日之前完成。股票的锁定期为自交易完成之日起四个月加一天</p>

<p>TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- <strong>Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)</strong> (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the “Offering”) in order to accommodate participation by a long-term existing investor.</p>
<div class="lb-trans"><p>多伦多，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)</strong>（“Profound” 或 “公司”）欣然宣布，已增加其于 2025 年 12 月 19 日之前宣布的私募配售规模（“发行”），以便容纳一位长期现有投资者的参与。</p>
</div><p>The Company will now raise gross proceeds of up to US$6.45 million in the Offering, through the issuance of up to 921,428 common shares at a price of US$7.00 per common share.</p>
<div class="lb-trans"><p>公司现在将在此次发行中筹集最多 645 万美元的毛收益，通过发行最多 921,428 股普通股，价格为每股 7.00 美元。</p>
</div><p>The common shares sold pursuant to the Offering will be subject to a hold period of four months plus one day from the closing date of the Offering. The closing of the Offering is expected to occur on or prior to December 30, 2025.</p>
<div class="lb-trans"><p>根据此次发行出售的普通股将受到四个月加一天的持有期限制，从发行的成交日期开始计算。预计此次发行的成交将在 2025 年 12 月 30 日或之前进行。</p>
</div><p>The Company intends to use the net proceeds from the Offering for expansion of its sales and marketing, working capital, research and development, strategic transactions and general corporate purposes.</p>
<div class="lb-trans"><p>公司打算将此次发行的净收益用于扩大销售和市场营销、营运资金、研发、战略交易和一般企业用途。</p>
</div><p>No securities will be sold under the Offering to United States purchasers and this press release is not an offer to sell or the solicitation of an offer to buy such securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered under the Offering have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.</p>
<div class="lb-trans"><p>此次发行下不会向美国购买者出售任何证券，本新闻稿不构成在美国或任何在该司法管辖区内此类要约、招揽或销售在未符合或注册该司法管辖区证券法之前的要约。根据此次发行提供的证券尚未，也不会根据美国证券法进行注册，并且在未注册或适用的美国注册要求和适用的美国州证券法的豁免情况下，这些证券不得在美国境内或向美国人士提供或出售。</p>
</div><p><strong>About Profound Medical Corp.</strong></p>
<div class="lb-trans"><p><strong>关于 Profound Medical Corp.</strong></p>
</div><p>Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.</p>
<div class="lb-trans"><p>Profound 是一家商业阶段的医疗设备公司，开发和销售基于人工智能的、MRI 引导的、无切口的疾病组织消融疗法。</p>
</div><p>Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).</p>
<div class="lb-trans"><p>Profound 正在商业化 TULSA-PRO®，这是一项结合实时 MRI、AI 增强规划、机器人驱动的经尿道超声和闭环温度反馈控制的技术。使用 TULSA-PRO 系统进行的 TULSA 程序™有潜力成为整个前列腺疾病谱的主流治疗方式；涵盖低、中、高风险前列腺癌；同时适用于同时患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；仅患有 BPH 的男性；以及需要针对放射性复发局部前列腺癌进行挽救治疗的患者。TULSA 程序采用实时 MRI 引导，以精确保护患者的尿失禁和性功能，同时通过精确的声波吸收技术将目标前列腺组织加热至 55-57°C。TULSA 是一种无切口和无辐射的 “一次性” 程序，在单次会话中完成，耗时数小时。几乎所有形状和大小的前列腺都可以安全、有效和高效地使用 TULSA 进行治疗。该程序没有出血；不需要住院；大多数 TULSA 患者报告迅速恢复到正常日常生活。TULSA-PRO 已获得 CE 标记、加拿大卫生部批准，并获得美国食品药品监督管理局（“FDA”）的 510(k) 清关。</p>
</div><p>Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.</p>
<div class="lb-trans"><p>Profound 还在商业化 Sonalleve®，这是一种创新的治疗平台，已获得 CE 标记，用于治疗子宫肌瘤、腺肌症、骨转移疼痛缓解、纤维瘤和骨样骨瘤。Sonalleve 还获得了中国国家药品监督管理局的批准，用于无创治疗子宫肌瘤，并在美国获得人道设备豁免下的 FDA 批准，用于治疗骨样骨瘤。Profound 正在早期阶段探索 Sonalleve 的其他潜在治疗市场，该技术已显示出临床应用，例如无创消融腹部癌症和癌症治疗的高温疗法。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, statements relating to the Company’s anticipated use of proceeds and the closing of the Offering. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.</p>
<div class="lb-trans"><p>本公告包含关于 Profound 及其业务的前瞻性声明，这些声明可能包括但不限于与公司预期的收益使用和发行结束相关的声明。通常，但并非总是，前瞻性声明可以通过使用诸如 “计划”、“预计”、“期望”、“安排”、“打算”、“考虑”、“预期”、“相信”、“提议” 或这些词语和短语的变体（包括否定变体）来识别，或者声明某些行动、事件或结果 “可能”、“可以”、“将”、“可能会” 或 “将会” 被采取、发生或实现。这些声明基于 Profound 管理层当前的预期。本公告中讨论的前瞻性事件和情况，可能不会在某些特定日期之前发生，或者根本不会发生，并且可能因影响公司的已知和未知风险因素和不确定性而有实质性差异。尽管 Profound 已尝试识别可能导致实际行动、事件或结果与前瞻性声明中描述的内容有实质性差异的重要因素，但可能还有其他因素导致行动、事件或结果与预期、估计或打算的内容有所不同。没有任何前瞻性声明可以得到保证。可能导致实际结果与前瞻性声明中所列内容有实质性差异的其他因素和风险已在 Profound 的 10-K 表格年度报告及其他向美国和加拿大证券监管机构提交的文件中进行了描述，这些文件可在 www.sedarplus.ca 和 www.sec.gov 获取。除非适用的证券法要求，否则前瞻性声明仅在作出声明的日期有效，Profound 没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律另有要求的除外。</p>
</div><p><strong>For further information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p>Stephen Kilmer</p>
<div class="lb-trans"><p>Stephen Kilmer</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>skilmer@profoundmedical.com</p>
<div class="lb-trans"><p>skilmer@profoundmedical.com</p>
</div><p>T: 647.872.4849</p>
<div class="lb-trans"><p>电话：647.872.4849</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXlOeU0zTXpNMU9UazFJekl3TVRnMU5EYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNzAyNyM3MzM1OTk1IzIwMTg1NDc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjEwNzdjNjItZTFkOC00ZmE4LTlkMGItMjU4YjAxOTcwNzgxLTEwMzAxMTktMjAyNS0xMi0yNC1lbg==/tiny/Profound-Medical-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MjEwNzdjNjItZTFkOC00ZmE4LTlkMGItMjU4YjAxOTcwNzgxLTEwMzAxMTktMjAyNS0xMi0yNC1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

Profound Medical Corp.宣布扩大私募规模 | PROF 股票新闻